{"id":829954,"date":"2025-03-26T08:12:13","date_gmt":"2025-03-26T12:12:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-nipocalimab-data-and-real-world-research-at-aan-2025-highlight-positive-phase-3-results-and-commitment-to-people-living-with-generalized-myasthenia-gravis-gmg\/"},"modified":"2025-03-26T08:12:13","modified_gmt":"2025-03-26T12:12:13","slug":"new-nipocalimab-data-and-real-world-research-at-aan-2025-highlight-positive-phase-3-results-and-commitment-to-people-living-with-generalized-myasthenia-gravis-gmg","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-nipocalimab-data-and-real-world-research-at-aan-2025-highlight-positive-phase-3-results-and-commitment-to-people-living-with-generalized-myasthenia-gravis-gmg\/","title":{"rendered":"New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa<\/sup> score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+<\/i>\n <\/p>\n

\n Nipocalimab data demonstrate longer-term sustained disease control as measured by<\/i>
\n MG-ADLb<\/sup> and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study <\/i>\n <\/p>\n

\n Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024<\/span> and was granted U.S. FDA Priority Review for the treatment of gMG\u00a0<\/i>\n <\/p>\n

\n Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids <\/i>\n <\/p>\n

\n
\n SPRING HOUSE, Pa.<\/span>
\n <\/span>, March 26, 2025<\/span><\/span> \/PRNewswire\/ — Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company’s innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5<\/span> \u2013 9 in San Diego, California<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Johnson
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Oral and poster presentations include data from the pivotal Phase 3 Vivacity-MG3 study of nipocalimab <\/b>in gMG, which was included in the U.S. Biologics License Application (BLA) for nipocalimab:<\/p>\n